Drugs · acquisition-cost intelligence
STEGLUJAN
ertugliflozin and sitagliptin· ingredient ertugliflozinCombinations of oral blood glucose lowering drugs· ERTUGLIFLOZIN PIDOLATE 15 mg/1; SITAGLIPTIN PHOSPHATE 100 mg/1; ERTUGLIFLOZIN PIDOLATE 5 mg/1; SITAGLIPTIN PHOSPHATE 100 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$17.54
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-06-182026-05-20
Same-ingredient options by acquisition cost
Other ertugliflozin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| SEGLUROMET | $5.72 | −$11.81 |
| STEGLATRO | $11.43 | −$6.11 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.